Nicholas A. Forward
Halifax, NS B3H4R2, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and/or Refractory Follicular Lymphoma.
Journal: Current oncology (Toronto, Ont.)
Published: June 06, 2026
Novel proteomic characterization of multiple myeloma bone marrow interstitial fluid links prognosis to coagulation pathways.
Journal: Clinical proteomics
Published: July 21, 2025
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma.
Journal: Future oncology (London, England)
Published: June 19, 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 08, 2025
PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL.
Journal: European journal of haematology
Published: November 28, 2022
A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
Journal: Current oncology (Toronto, Ont.)
Published: August 20, 2022
DMG26: A Targeted Sequencing Panel for Mutation Profiling to Address Gaps in the Prognostication of Multiple Myeloma.
Journal: The Journal of molecular diagnostics : JMD
Published: February 03, 2021
Low-depth sequencing for copy number abnormalities in multiple myeloma supersedes fluorescent in situ hybridization in scope and resolution.
Journal: Clinical genetics
Published: February 08, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026